Brotizolam

CHEMBL32479 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

393.7 g/mol

LogP

2.8

Phase

4

A thienodiazepine drug with sedative, hypnotic, and anxiolytic properties, used in some countries for the short-term treatment of insomnia and anxiety. It acts on GABA-A receptors similarly to benzodiazepines to promote sleep and reduce anxiety. Risk of tolerance, dependence, and withdrawal limits its use to short-term treatment.

分子量

393.7000 g/mol

LogP

2.80

TPSA

71.30 Å²

Lipinski 五规则

符合

治疗领域

Schizophrenia Generalized Anxiety Disorder Insomnia

作用机制

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2

InChI

InChI=1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3

Molecular Formula

C15H10BrClN4S

HBD / HBA

- / 4

可旋转键数

1

重原子数

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A thienodiazepine drug with sedative, hypnotic, and anxiolytic properties, used in some countries for the short-term treatment of insomnia and anxiety. It acts on GABA-A receptors similarly to benzodiazepines to promote sleep and reduce anxiety. Risk of tolerance, dependence, and withdrawal limits its use to short-term treatment.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Brotizolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL32479. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2451. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

正在寻找患者友好型信息？

Brotizolam 在 PillFYI 上

结构

快速数据

分子式: C15H10BrClN4S

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.